Bayer’s initiative reflects a broader effort to address the high unmet medical need in oncology. The trial’s success could ...

Bayer announced a $10 billion global settlement in June 2020 ... it alleges that the defendants advanced in pursuit of the merger despite being aware that acquiring Monsanto brought significant risks, ...

Bayer initiates phase I study with SOS1 inhibitor, BAY3498264 in patients with advanced KRAS-mutated tumours: Berlin Saturday, December 14, 2024, 13:00 Hrs [IST] Bayer announced i ...

Sky Germany reports that Bayer Leverkusen are in advanced talks with Victor Boniface to extend his contract by a year until ...

Barcelona sporting director Deco met with Bayer Leverkusen defender Jonathan Tah and his agents to explore the possibility of ...

Bayer announced today initiation of a Phase I clinical trial with BAY3498264, an investigational oral selective Son of Sevenless Homologue 1 (SOS1) inhibitor. The open-label, first-in-human, dose ...